Literature DB >> 31531788

Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.

Eric Aliotta1,2, Prem P Batchala3, David Schiff4, Beatriz M Lopes5, Jason T Druzgal3, Sugoto Mukherjee3, Sohil H Patel3.   

Abstract

PURPOSE: Diffuse lower grade gliomas (LGG) with isocitrate dehydrogenase (IDH) gene mutations (IDHMUT) have a distinct survival advantage compared with IDH wild-type (IDHWT) cases but the mechanism underlying this disparity is not well understood. Diffusion Tensor Imaging (DTI) has identified infiltrated non-enhancing tumor regions that are characterized by low isotropic (p) and high anisotropic (q) diffusion tensor components that associate with poor survival in glioblastoma. We hypothesized that similar regions are more prevalent in IDHWT (vs. IDHMUT) LGG.
METHODS: p and q maps were reconstructed from preoperative DTI scans in N = 41 LGG patients with known IDH mutation and 1p/19q codeletion status. Enhancing and non-enhancing tumor volumes were autosegmented from standard (non-DTI) MRI scans. Percentage non-enhancing tumor volumes exhibiting low p and high q (Vinf) were then determined using threshold values (p = 2 × 10-3mm2/s, q = 3 × 10-4 mm2/s) and compared between IDHWT and IDHMUT LGG, and between IDHMUT LGG with and without 1p/19q codeletion.
RESULTS: Vinf volumes were significantly larger in IDHWT LGG than in IDHMUT LGG (35.4 ± 18.3% vs. 15.9 ± 7.6%, P < 0.001). Vinf volumes did not significantly differ between IDHMUT LGG with and without 1p/19q codeletion (17.1 ± 9.5% vs. 14.8 ± 5.8%, P = 1.0).
CONCLUSION: IDHWT LGG exhibited larger volumes with suppressed isotropic diffusion (p) and high anisotropic diffusion (q) which reflects regions with increased cell density but non-disrupted neuronal structures. This may indicate a greater prevalence of infiltrative tumor in IDHWT LGG.

Entities:  

Keywords:  Diffusion tensor imaging; Genetic classification; IDH mutation; Low grade glioma

Mesh:

Substances:

Year:  2019        PMID: 31531788     DOI: 10.1007/s11060-019-03291-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.

Authors:  Ji Xiong; Wenli Tan; Jianbo Wen; Jiawei Pan; Yin Wang; Jun Zhang; Daoying Geng
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

2.  Brain Cancer Imaging Phenomics Toolkit (brain-CaPTk): An Interactive Platform for Quantitative Analysis of Glioblastoma.

Authors:  Saima Rathore; Spyridon Bakas; Sarthak Pati; Hamed Akbari; Ratheesh Kalarot; Patmaa Sridharan; Martin Rozycki; Mark Bergman; Birkan Tunc; Ragini Verma; Michel Bilello; Christos Davatzikos
Journal:  Brainlesion       Date:  2018-02-17

3.  Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.

Authors:  C-C Wu; R Jain; A Radmanesh; L M Poisson; W-Y Guo; D Zagzag; M Snuderl; D G Placantonakis; J Golfinos; A S Chi
Journal:  AJNR Am J Neuroradiol       Date:  2018-09-06       Impact factor: 3.825

4.  Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Authors:  David Capper; Susanne Weissert; Jörg Balss; Antje Habel; Jochen Meyer; Diana Jäger; Ulrike Ackermann; Claudia Tessmer; Andrey Korshunov; Hanswalter Zentgraf; Christian Hartmann; Andreas von Deimling
Journal:  Brain Pathol       Date:  2009-10-27       Impact factor: 6.508

5.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.

Authors:  Maarten M J Wijnenga; Pim J French; Hendrikus J Dubbink; Winand N M Dinjens; Peggy N Atmodimedjo; Johan M Kros; Marion Smits; Renske Gahrmann; Geert-Jan Rutten; Jeroen B Verheul; Ruth Fleischeuer; Clemens M F Dirven; Arnaud J P E Vincent; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

6.  Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation.

Authors:  Konstantinos Kamnitsas; Christian Ledig; Virginia F J Newcombe; Joanna P Simpson; Andrew D Kane; David K Menon; Daniel Rueckert; Ben Glocker
Journal:  Med Image Anal       Date:  2016-10-29       Impact factor: 8.545

7.  Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study.

Authors:  S J Price; R Jena; N G Burnet; P J Hutchinson; A F Dean; A Peña; J D Pickard; T A Carpenter; J H Gillard
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

8.  Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.

Authors:  Jörg Felsberg; Marietta Wolter; Heike Seul; Britta Friedensdorf; Matthias Göppert; Michael C Sabel; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2010-02-04       Impact factor: 15.887

9.  Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling.

Authors:  Joseph M Foster; Assa Oumie; Fiona S Togneri; Fabiana Ramos Vasques; Debra Hau; Morag Taylor; Emma Tinkler-Hundal; Katie Southward; Paul Medlow; Keith McGreeghan-Crosby; Iris Halfpenny; Dominic J McMullan; Phil Quirke; Katherine E Keating; Mike Griffiths; Karen G Spink; Fiona Brew
Journal:  BMC Med Genomics       Date:  2015-02-18       Impact factor: 3.063

10.  Tissue signature characterisation of diffusion tensor abnormalities in cerebral gliomas.

Authors:  Stephen J Price; Alonso Peña; Neil G Burnet; Raj Jena; Hadrian A L Green; T Adrian Carpenter; John D Pickard; Jonathan H Gillard
Journal:  Eur Radiol       Date:  2004-06-25       Impact factor: 5.315

View more
  1 in total

Review 1.  Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors.

Authors:  Francesco Sanvito; Antonella Castellano; Andrea Falini
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.